SCYX
SCYNEXIS INC
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$4.46
+0.22%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$4.49
From 52W high−50.22%
Volume68810.00
Market cap$44.38M
P/E (TTM)—
P/S (TTM)2.3x
Div yield—
Key dataSep 18, 2026
Open
$4.49
From 52W high
−50.22%
Volume
68810.00
Market cap
$44.38M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.8x
P/E (TTM)
—
RSI (14)
42.2
MomentumView details →
1D Return
+0.22%
YTD Return
−11.26%
SummaryUpdated Jun 1, 2026
SCYNEXIS, Inc. (NASDAQ:SCYX) is a biotechnology company founded in 1999 and headquartered in Jersey City, New Jersey. The company went public in May 2014 and specializes in developing antifungal treatments, with a particular focus on addressing serious and life-threatening fungal infections. SCYNEXIS has successfully brought its first commercial product, BREXAFEMME, to market and continues to develop its lead compound ibrexafungerp for various fungal indications through clinical trials and strategic partnerships.
Similar companies
Latest newsMore news →
SCYNEXIS Inc. appointed Sanjay Subramanian as Chief Financial Officer effective September 9, 2026.10d agoSCYNEXIS Inc. Chief Financial Officer Ivor Macleod retired effective September 9, 2026.10d agoSCYNEXIS, Inc. granted an inducement equity award to a new Senior Director in connection with the commencement of employment, approved under Nasdaq Listing Rule 5635(c)(4).26d ago